CureVac N.V. CVAC · NASDAQ
$4.64 -0.75% (-$0.04)
Summary
81 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 38 EUR is left as net profit.
- Revenue grew by 57% a year over the last 3 years.
- It earns 39 EUR a year on every 100 EUR of invested capital.
- The share price is below the Bulios Fair Price.
What to watch
- It missed profit estimates 5 times in the last 8 quarters.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 4.6 EUR for 1 EUR of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (EUR)
- Analyst estimate
Revenue grew by 98% a year over 5 years. Over the last 3 years it grew by 57% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 2
- Hold 5
- Sell 1
No analyst has published a price target.
25% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.